The therapeutic effect of targeted kinase inhibitors can be significantly reduced by intrinsic or 13 acquired resistance mutations that modulate the affinity of the drug for the kinase. In cancer, the majority of 14 missense mutations are rare, making it difficult to predict their impact on inhibitor affinity. This complicates 15 the practice of precision medicine, pairing of patients with clinical trials, and development of next-generation 16 inhibitors. Here, we examine the potential for alchemical free-energy calculations to predict how kinase 17 mutations modulate inhibitor affinities to Abl, a major target in chronic myelogenous leukemia (CML). We 18 find these calculations can achieve useful accuracy in predicting resistance for a set of eight FDA-approved 19 kinase inhibitors across 144 clinically-identified point mutations, achieving a root mean square error in 20 binding free energy changes of 1.1 1.3 0.9 kcal/mol (95% confidence interval) and correctly classifying mutations 21 as resistant or susceptible with 88 93 82 % accuracy. Since these calculations are fast on modern GPUs, this 22 basket trials [21, 22], help prioritize candidate compounds for clinical trials, and aid the development of 40 next-generation inhibitors.
benchmark establishes the potential for physical modeling to collaboratively support the rapid assessment 23 and anticipation of the potential for patient mutations to affect drug potency in clinical applications. 24 25 Targeted kinase inhibitors are a major therapeutic class in the treatment of cancer. A total of 38 selective 26 small molecule kinase inhibitors have now been approved by the FDA [1] , including 34 approved to treat 27 cancer, and perhaps 50% of all current drugs in development target kinases [2] . Despite the success of 28 selective inhibitors, the emergence of drug resistance remains a challenge in the treatment of cancer [3-10] 29 and has motivated the development of second-and then third-generation inhibitors aimed at overcoming 30 recurrent resistance mutations [11] [12] [13] [14] [15] . 31 While a number of drug resistance mechanisms have been identified in cancer (e.g., induction of splice 32 variants [16] , or alleviation of feedback [17] ), inherent or acquired missense mutations in the kinase domain 33 of the target of therapy are a major form of resistance to tyrosine kinase inhibitors (TKI) [10, 18, 19] . Oncology 34 is entering a new era with major cancer centers now deep sequencing tumors to reveal genetic alterations 35 that may render subclonal populations susceptible or resistant to targeted inhibitors [20] , but the use of 36 this information in precision medicine has lagged behind. It would be of enormous value in clinical practice 37 if an oncologist could reliably ascertain whether these mutations render the target of therapy resistant or 38 susceptible to available inhibitors; such tools would facilitate the enrollment of patients in mechanism-based 39 1 of 37 [20] show that 68.5% of missense kinase mutations in cancer patients have never been observed previously, while 87.4% have been observed no more than ten times. (b) To compute the impact of a clinical point mutation on inhibitor binding free energy, a thermodynamic cycle can be used to relate the free energy of the wild-type and mutant kinase in the absence (top) and presence (bottom) of the inhibitor. (c) Summary of mutations studied in this work. Frequency of the wild-type (dark green) and mutant (green) residues for the 144 clinically-identified Abl mutations used in this study (see Table 1 for data sources). Also shown is the frequency of residues within 5 Å (light blue) and 8 Å (blue) of the binding pocket. The number of wild-type Phe residues (n=45) and mutant Val residues (n=31) exceeded the limits of the y-axis. Number of Resistant, Susceptical mutants using 10-fold affinity change threshold. PDB: Source PDB ID, or Dock to 3ue4, which used 3ue4 as the receptor for Glide-SP docking inhibitors without co-crystal structure. Δ WT : Binding free energy of inhibitor to wild-type Abl, as estimated from IC 50 data.
which co-crystal structures were not available (Abl:erlotinib and Abl:gefitinib) and used docking to generate 110 initial coordinates. 111 Compiled ΔpIC 50 data provides a benchmark for predicting mutational resistance 112 To construct a benchmark evaluation dataset, we compiled a total of 144 ΔpIC 50 measurements of Abl:TKI 113 affinities, summarized in Table 1 , taking care to ensure all measurements for an individual TKI were reported 114 in the same study from experiments run under identical conditions. 131 ΔpIC 50 measurements were available 115 across the six TKIs with available co-crystal structures with wild-type Abl-26 for axitinib and 21 for bosutinib, 116 dasatinib, imatinib, nilotinib, and ponatinib. 13 ΔpIC 50 measurements were available for the two TKIs for 117 which docking was necessary to generate Abl:TKI structures-7 for erlotinib and 6 for gefitinib. For added 118 diversity, this set includes TKIs for which Abl is not the primary target-axitinib, erlotinib, and gefitinib. All 119 mutations in this benchmark dataset have been clinically-observed (Table S1 ). Due to the change in bond 120 topology required by mutations involving proline, which is not currently supported by the FEP+ technology for 121 protein residue mutations, the three mutations H396P (axitinib, gefitinib, erlotinib) were excluded from our 122 assessment. As single point mutations were highly represented in the IMPACT study analyzed in Figure 1a , 123 we excluded double mutations from this work. However, the impact of mutations from multiple sites can 124 potentially be modeled by sequentially mutating each site and this will be addressed in future work. 125 Experimental ΔpIC 50 measurements for wild-type and mutant Abl were converted to ΔΔG in order 126 to make direct comparisons between physics-based models and experiment. However, computation 127 of experimental uncertainties were required to understand the degree to which differences between 128 predictions and experimental data were significant. Since experimental error estimates for measured IC 50 s non-phosphorylated models, when comparing sample statistics directly. In comparing 31 mutations for 139 which phosphorylated and non-phosphorylated Δ s were available, we found a strong correlation between 140 the ΔΔGs derived from those data (r=0.94, Supplementary Figure S1) ; the statistics of that comparison are 141 similar to those of the inter-lab variability comparison. 142 Most clinical mutations do not significantly reduce TKI potency 143 The majority of mutations do not lead to resistance by our 10-fold affinity loss threshold: 86.3% of the 144 co-crystal set (n=113) and 86.8% of the total set (n=125). Resistance mutations, which are likely to result in a 145 failure of therapy, constitute 13.7% of the co-crystal set (n=18) and 13.2% of the total set of mutations (n=19). 146 The ΔpIC 50 s for all 144 mutations are summarized in Table S2 - Table S7 in the Supplementary Information. 147 Two mutations exceeded the dynamic range of the assays (IC 50 >10,000 nM); as these two mutations clearly 148 raise resistance, we excluded them from quantitative analysis (RMSE and MUE) but included them in truth 149 table analyses and classification metrics (accuracy, specificity, sensitivity). 150 How accurately does physical modeling predict affinity changes for clinical Abl mutants? 151 From prior experience with relative alchemical free-energy calculations for ligand design, good initial receptor-152 ligand geometry was critical to obtaining accurate and reliable free energy predictions [29] , so we first focused 153 on the 131 mutations in Abl kinase across six TKIs for which wild-type Abl:TKI co-crystal structures were 154 available. Figure 3 summarizes the performance of predicted binding free-energy changes (ΔΔG) for all 155 131 mutants in this set for both a fast MM-GBSA physics-based method that only captures interaction 156 energies for a single structure (Prime) and rigorous alchemical free-energy calculations (FEP+). Scatter plots from three independent runs for a particular mutation, while Prime results are deterministic and are not 163 contaminated by statistical uncertainty (see Methods). 164 To better assess whether discrepancies between experimental and computed ΔΔ s simply arise for 165 known forcefield limitations or might indicate more significant effects, we incorporated an additional error 166 5 of 37 model in which the forcefield error was taken to be a random error FF ≈ 0.9 kcal/mol, a value established 167 form previous benchmarks on small molecules absent conformational sampling or protonation state 168 issues [25] . Thin error bars in Figure 2 represent the overall estimated error due to both this forcefield error 169 and experimental variability or statistical uncertainty. 170 To assess overall quantitative accuracy, we computed both root-mean-squared error (RMSE)-which is 171 rather sensitive to outliers, and mean unsigned error (MUE Figure S2) . For the alchemical approach, the two-class accuracy was 210 0.92 0.96 0.87 when an affinity change cutoff of 20-fold was used while using an affinity change cutoff of 100-fold 211 further improved the two-class accuracy to 0.98 1 The impact of point mutations on drug binding are not equally well predicted for the six TKIs. Four mutations, however, were misclassified to a degree that is statistically significant given their 95% con-264 8 of 37 although the T315A mutations for bosutinib, imatinib, nilotinib, and ponatinib were correctly classified as 266 susceptible, the predicted free energy changes for these four TKIs were consistently much more negative 267 than the corresponding experimental measurements, just as for dasatinib/T315A, indicating there might be a 268 generic driving force contributing to the errors in T315A mutations for these five TKIs. Abl is known to be able 269 to adopt many different conformations (including DFG-in and DFG-out), and it is very likely that the T315A 270 mutation will induce conformational changes in the apo protein [50], which was not adequately sampled in 271 the relatively short simulations, leading to the errors for T315A mutations for these TKIs. By comparison, 272 the T315I mutations for axitinib, bosutinib, imatinib, nilotinib, and ponatinib were all accurately predicted 273 with the exception of bosutinib/T315I being the only misprediction, suggesting an issue specific to bosutinib. 274 The complex electrostatic interactions between the 2,4-dichloro-5-methoxyphenyl ring in bosutinib and the lead to misprediction of these two mutations. 283 How accurately can the impact of mutations be predicted for docked TKIs? 284 To assess the potential for utilizing physics-based approaches in the absence of a high-resolution experimen-285 tal structure, we generated models of Abl bound to two TKIs-erlotinib and gefinitib-for which co-crystal 286 structures with wild-type kinase are not currently available. In Figure 5 , we show the Abl:erlotinib and 287 Abl:gefitinib complexes that were generated using a docking approach (Glide-SP, see Methods). These two Encouragingly, these results indicate that our initial models of Abl bound to erlotinib and gefitinib were 298 reliable because the accuracy and dependability of our FEP+ calculations were not sensitive to crystallographic 299 waters. Our secondary concern was the accuracy with which the approach classified mutations as resistant 300 or susceptible. 301 While the results presented in (Figure 5) indicate that FEP+ is capable of achieving good quantitative 302 accuracy when a co-crystal structure is unavailable, it is important to understand why a mutation was 303 predicted to be susceptible but was determined experimentally to be resistant. F317I was the one mutation 304 that increased resistance to erlotinib (or gefitinib) because it destabilized binding by more than 1.36 kcal/mol-305 means we are unable to confidently discern whether this mutation induces more than 10-fold resistance 307 to either TKI. Therefore, the one misclassification by FEP+ in Figure 5 is not statistically significant and the erlotinib docked to Abl (light gray) is depicted in green and erlotinib bound to EGFR (dark gray) is depicted in blue. The docked pose of Abl:gefitinib is superimposed on the co-crystal structure of EGFR:gefitinib; gefitinib docked to Abl (light gray) is depicted in green and gefitinib bound to EGFR (dark gray) is depicted in blue. The locations of clinical mutants for each inhibitor are highlighted (red spheres). The overall RMSEs and MUEs for Prime (center) and FEP+ (right) and two-class accuracies are also shown in the figure. Computed free energy changes due to the F317I mutation for erlotinib (-e) and gefitinib (-g) are highlighted in the scatter plot. FEP+ results are based on the docked models prepared with crystal waters added back while the Prime (an implicit solvent model) results are based on models without crystallographic water.
Physics-based modeling can reliably predict when a mutation elicits resistance to therapy 312 The results presented in this work are summarized in were a weighted average of scaled Prime and FEP+. However, this model also had no sensitivity. It appears 333 difficult to improve upon the predictive power of FEP+ by statistical operations. 334 To address the impact of picking a cutoff to classify predicted free energies as resistant or sensitizing, we Examining the physical and chemical features of outliers 353 Current alchemical approaches neglect effects that will continue to improve accuracy 354 The high accuracy of FEP+ is very encouraging, and the accuracy can be further improved with more accurate for alchemical free-energy methods such as FEP+ will take on increasingly integrated roles to impact projects. 416 This work illustrates how the domain of applicability for alchemical free-energy methods is much larger 417 than previously appreciated, and might further be found to include new areas as research progresses: to EGFR were publicly available and this information was used to obtain initial ligand geometries and to 471 establish a reference binding mode against which our docking results could be structurally scored. The Abl 472 receptor structure bound to bosutinib was used for docking because its structure was structurally similar to using a restraint force constant of 50 kcal/mol/Å 2 ; this Brownian dynamics integrator corresponds to a 526 Langevin integrator in the limit when →0, modified to stabilize equilibration of starting configurations 527 with high potential energies; particle and piston velocities were clipped so that particle displacements were per alchemical free-energy simulation (12 GPUs in total), requiring ∼6 hours in total to compute ΔΔG.
548
Obtaining ΔΔG from ΔpIC 50 benchmark set data 549 Reference relative free energies were obtained from three publicly available sources of ΔpIC 50 data ( Table 1) . 550 Under the assumption of Michaelis-Menten binding kinetics (pseudo first-order, but relative free energies are 551 likely consistent), the inhibitor is competitive with ATP (Equation 1) . This assumption has been successfully 552 used to estimate relative free energies [37, 82-84] using the relationship between IC 50 and competitive 553 inhibitor affinity ,
If the Michaelis constant for ATP ( ) is much larger than the initial ATP concentration 0 , the relation in 
where IC 50, is the IC 50 value for the TKI binding to the wild-type protein and IC 50, is the IC 50 value for the 558 mutant protein. is the ideal gas constant and is taken to be room temperature (300 K). 559 As alluded to above, relating ΔpIC 50 s to ΔΔGs assumes that the Michaelis constant for ATP is much larger 560 than the initial concentration of ATP, and that the experimentally observed ΔpIC 50 change is solely from Bayesian hierarchical model to estimate intrinsic error 607 We used Bayesian inference to estimate the true underlying prediction error of Prime and FEP+ by making 608 use of known properties of the experimental variability (characterized in Figure 2 ) and statistical uncertainty 609 estimates generated by our calculations under weak assumptions about the character of the error. 610 We presume the true free energy differences of mutation , ΔΔ true , comes from a normal background 611 distribution of unknown mean and variance, 612 ΔΔ true ∼  ( mut , 2 mut ) = 1, … ,
18 of 37 where there are mutations in our dataset. We assign weak priors to the mean and variance 613 mut ∼ (−6, +6) (4) mut ∝ 1 (5)
where we limit > 0. 614 We presume the true computational predictions (absent statistical error) differ from the (unknown) 615 true free energy difference of mutation ΔΔ true by normally-distributed errors with zero bias but standard 616 deviation equal to the RMSE for either Prime or FEP+, the quantity we are focused on estimating:
In the case of Prime, since the computation is deterministic, we actually calculate ΔΔ true Prime for each 618 mutant. For FEP+, however, the computed free energy changes are corrupted by statistical error, which we 619 also presume to be normally distributed with standard deviation calc, , 620
where ΔΔ ,FEP+ is the free energy computed for mutant by FEP+, and ,FEP+ is the corresponding statistical 621 error estimate. 622 The experimental data we observe is also corrupted by error, which we presume to be normally dis- • Figure S1 : Comparison of 31 mutations for which phosphorylated and non-phosphorylated Δ s were 911 available.
912
• Figure S2 : Truth tables with varying classification cutoffs for each TKI. 913 • Figure S3 : ROC curves for non-scaled and scaled FEP+, non-scaled and scaled Prime, a consensus 914 model and a naïve model. 915 • Table S1 : IC 50 experiment-derived reference ΔΔG data. 916 • Table S2 : Axitinib: experimental IC 50 data and alchemical free-energy ΔΔGs.
917
• Table S3 : Bosutinib: experimental IC 50 data and alchemical free-energy ΔΔGs.
918
• Table S4 : Dasatinib: experimental IC 50 data and alchemical free-energy ΔΔGs.
919
• Table S5 : Imatinib: experimental IC 50 data and alchemical free-energy ΔΔGs.
920
• Table S6 : Nilotinib: experimental IC 50 data and alchemical free-energy ΔΔGs.
921
• Table S7 : Ponatinib: experimental IC 50 data and alchemical free-energy ΔΔGs.
922
• Table S8 : Summary of statistics of scaled predictions, a naïve model, and a consensus model. 923 • Table S9 : Summary of the preparation of the 6 Abl:TKI co-crystal structure complexes. T315I was beyond the concentration limit of the assay (10,000 nM).
BAR err:
Bennett Acceptance Ratio error.
ΔΔG : Average of three independent FEP+ runs. SE: Standard Error between three independent FEP+ runs. T315I was beyond the concentration limit of the assay (10,000 nM).
ΔΔG : Average of three independent FEP+ runs. SE: Standard Error between three independent FEP+ runs. ΔΔG : Average of three independent FEP+ runs. SE: Standard Error between three independent FEP+ runs. ΔΔG : Average of three independent FEP+ runs. SE: Standard Error between three independent FEP+ runs. 
